IRIS Accounts Production v26.1.0.640 00592506 Board of Directors 30.9.25 1.10.24 30.9.25 30.9.25 Medium entities These accounts have been prepared in accordance with the provisions applicable to companies subject to the medium-sized companies regime. true true true false true true false false false false false false false true false Ordinary 0 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh005925062024-09-30005925062025-09-30005925062024-10-012025-09-30005925062023-09-30005925062023-10-012024-09-30005925062024-09-3000592506ns15:EnglandWales2024-10-012025-09-3000592506ns14:PoundSterling2024-10-012025-09-3000592506ns10:Director12024-10-012025-09-3000592506ns10:Consolidated2025-09-3000592506ns10:ConsolidatedGroupCompanyAccounts2024-10-012025-09-3000592506ns10:PrivateLimitedCompanyLtd2024-10-012025-09-3000592506ns10:Consolidatedns10:MediumEntities2024-10-012025-09-3000592506ns10:Consolidatedns10:Audited2024-10-012025-09-3000592506ns10:Medium-sizedCompaniesRegimeForDirectorsReport2024-10-012025-09-3000592506ns10:Medium-sizedCompaniesRegimeForAccounts2024-10-012025-09-3000592506ns10:Consolidated2024-10-012025-09-3000592506ns10:Consolidatedns10:Medium-sizedCompaniesRegimeForDirectorsReport2024-10-012025-09-3000592506ns10:Medium-sizedCompaniesRegimeForAccountsns10:Consolidated2024-10-012025-09-3000592506ns10:FullAccounts2024-10-012025-09-3000592506ns5:Subsidiary12024-10-012025-09-3000592506ns5:Subsidiary22024-10-012025-09-3000592506ns5:Subsidiary32024-10-012025-09-3000592506ns5:Associate12024-10-012025-09-300059250612024-10-012025-09-3000592506ns10:OrdinaryShareClass12024-10-012025-09-3000592506ns10:Director22024-10-012025-09-3000592506ns10:Director32024-10-012025-09-3000592506ns10:CompanySecretary12024-10-012025-09-3000592506ns10:RegisteredOffice2024-10-012025-09-3000592506ns10:Consolidated2023-10-012024-09-3000592506ns5:CurrentFinancialInstruments2025-09-3000592506ns5:CurrentFinancialInstruments2024-09-3000592506ns5:Non-currentFinancialInstruments2025-09-3000592506ns5:Non-currentFinancialInstruments2024-09-3000592506ns5:ShareCapital2025-09-3000592506ns5:ShareCapital2024-09-3000592506ns5:CapitalRedemptionReserve2025-09-3000592506ns5:CapitalRedemptionReserve2024-09-3000592506ns5:FurtherSpecificReserve2ComponentTotalEquity2025-09-3000592506ns5:FurtherSpecificReserve2ComponentTotalEquity2024-09-3000592506ns5:RetainedEarningsAccumulatedLosses2025-09-3000592506ns5:RetainedEarningsAccumulatedLosses2024-09-3000592506ns5:ShareCapital2023-09-3000592506ns5:RetainedEarningsAccumulatedLosses2023-09-3000592506ns5:CapitalRedemptionReserve2023-09-3000592506ns5:FurtherSpecificReserve2ComponentTotalEquity2023-09-3000592506ns5:RetainedEarningsAccumulatedLosses2023-10-012024-09-3000592506ns5:CapitalRedemptionReserve2023-10-012024-09-3000592506ns5:FurtherSpecificReserve2ComponentTotalEquity2023-10-012024-09-3000592506ns5:RetainedEarningsAccumulatedLosses2024-10-012025-09-3000592506ns5:CapitalRedemptionReserve2024-10-012025-09-3000592506ns5:FurtherSpecificReserve2ComponentTotalEquity2024-10-012025-09-3000592506ns5:IntangibleAssetsOtherThanGoodwill2024-10-012025-09-3000592506ns5:PatentsTrademarksLicencesConcessionsSimilar2024-10-012025-09-3000592506ns5:OwnedOrFreeholdAssetsns5:LandBuildings2024-10-012025-09-3000592506ns5:PlantMachinery2024-10-012025-09-3000592506ns5:FurnitureFittings2024-10-012025-09-3000592506ns5:MotorVehicles2024-10-012025-09-3000592506ns5:ComputerEquipment2024-10-012025-09-3000592506ns5:PatentsTrademarksLicencesConcessionsSimilar2024-09-3000592506ns5:PatentsTrademarksLicencesConcessionsSimilar2025-09-3000592506ns5:PatentsTrademarksLicencesConcessionsSimilar2024-09-3000592506ns5:LandBuildings2024-09-3000592506ns5:PlantMachinery2024-09-3000592506ns5:FurnitureFittings2024-09-3000592506ns5:LandBuildings2024-10-012025-09-3000592506ns5:LandBuildings2025-09-3000592506ns5:PlantMachinery2025-09-3000592506ns5:FurnitureFittings2025-09-3000592506ns5:LandBuildings2024-09-3000592506ns5:PlantMachinery2024-09-3000592506ns5:FurnitureFittings2024-09-3000592506ns5:MotorVehicles2024-09-3000592506ns5:ComputerEquipment2024-09-3000592506ns5:MotorVehicles2025-09-3000592506ns5:ComputerEquipment2025-09-3000592506ns5:MotorVehicles2024-09-3000592506ns5:ComputerEquipment2024-09-3000592506ns5:CostValuation2024-09-3000592506ns5:CostValuation2025-09-30005925061ns5:Subsidiary12024-10-012025-09-3000592506ns5:Subsidiary12025-09-3000592506ns5:Subsidiary12024-09-3000592506ns5:Subsidiary12023-10-012024-09-3000592506ns5:Subsidiary232024-10-012025-09-3000592506ns5:Subsidiary22025-09-3000592506ns5:Subsidiary22024-09-30005925065ns5:Subsidiary32024-10-012025-09-3000592506ns5:Subsidiary32025-09-3000592506ns5:Subsidiary32024-09-3000592506ns5:Subsidiary32023-10-012024-09-3000592506ns5:Associate112024-10-012025-09-3000592506ns5:Associate12025-09-3000592506ns5:Associate12024-09-3000592506ns5:Associate12023-10-012024-09-3000592506ns5:WithinOneYearns5:CurrentFinancialInstruments2025-09-3000592506ns5:WithinOneYearns5:CurrentFinancialInstruments2024-09-3000592506ns5:Non-currentFinancialInstrumentsns5:BetweenOneTwoYears2025-09-3000592506ns5:Non-currentFinancialInstrumentsns5:BetweenOneTwoYears2024-09-3000592506ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2025-09-3000592506ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2024-09-3000592506ns5:WithinOneYearns5:CurrentFinancialInstrumentsns5:HirePurchaseContracts2025-09-3000592506ns5:WithinOneYearns5:CurrentFinancialInstrumentsns5:HirePurchaseContracts2024-09-3000592506ns5:HirePurchaseContractsns5:BetweenOneFiveYears2025-09-3000592506ns5:HirePurchaseContractsns5:BetweenOneFiveYears2024-09-3000592506ns5:HirePurchaseContracts2025-09-3000592506ns5:HirePurchaseContracts2024-09-3000592506ns5:WithinOneYear2025-09-3000592506ns5:WithinOneYear2024-09-3000592506ns5:BetweenOneFiveYears2025-09-3000592506ns5:BetweenOneFiveYears2024-09-3000592506ns5:MoreThanFiveYears2025-09-3000592506ns5:MoreThanFiveYears2024-09-3000592506ns5:AllPeriods2025-09-3000592506ns5:AllPeriods2024-09-3000592506ns5:DeferredTaxation2024-09-3000592506ns5:DeferredTaxation2024-10-012025-09-3000592506ns5:DeferredTaxation2025-09-3000592506ns10:OrdinaryShareClass12025-09-3000592506ns5:RetainedEarningsAccumulatedLosses2024-09-3000592506ns5:CapitalRedemptionReserve2024-09-3000592506ns5:FurtherSpecificReserve2ComponentTotalEquity2024-09-30
REGISTERED NUMBER: 00592506 (England and Wales)












Group Strategic Report,

Report of the Directors and

Consolidated Financial Statements

for the Year Ended 30 September 2025

for

Respirex International Limited

Respirex International Limited (Registered number: 00592506)






Contents of the Consolidated Financial Statements
for the Year Ended 30 September 2025




Page

Company Information 1

Group Strategic Report 2

Report of the Directors 4

Report of the Independent Auditors 5

Consolidated Income Statement 9

Consolidated Other Comprehensive Income 10

Consolidated Statement of Financial Position 11

Company Statement of Financial Position 12

Consolidated Statement of Changes in Equity 13

Company Statement of Changes in Equity 14

Consolidated Statement of Cash Flows 15

Notes to the Consolidated Statement of Cash Flows 16

Notes to the Consolidated Financial Statements 18


Respirex International Limited

Company Information
for the Year Ended 30 September 2025







DIRECTORS: M B Simpson
G Walker
A Burt



SECRETARY: D G Mackie



REGISTERED OFFICE: Shadwell House
65 Lower Green Road
Tunbridge Wells
Kent
TN4 8TW



REGISTERED NUMBER: 00592506 (England and Wales)



SENIOR STATUTORY AUDITOR: Aidan Smyth



AUDITORS: Peter Hodgson & Co. Ltd. (Statutory Auditor)
Chartered Accountants
Shadwell House
65 Lower Green Road
Tunbridge Wells
Kent
TN4 8TW

Respirex International Limited (Registered number: 00592506)

Group Strategic Report
for the Year Ended 30 September 2025


REVIEW OF BUSINESS
The year to 30th September 2025 showed much improved trading performance compared to 2024.

Despite record turnover and profits, Respirex's performance was still somewhat impaired by ongoing supply chain issues. However, the group gained a significant number of major new customers during the year and the order book was at a record high at the financial year end. The first months of the new financial year are yielding very significant growth mostly being driven by the launch of new products.

The performance of MFC International Ltd. improved dramatically despite the reported financial results. The loss for the year was cut to £143.5k compared to a loss of £517.9k in 2024. We are now seeing some substantial orders coming through and the extensive investment in people, technology and research & development is beginning to pay off. The accounts for 2025-26 are so far showing much increased levels of turnover and reported profits.

Our German subsidiary, Respirex GmbH made a profit of £11.6k in the year.

The group invested a further £456k in property and equipment in the year.

The group continues to hold higher than usual levels of stock in order to hedge against higher costs and delivery charges and to avoid raw material shortages.

FINANCIAL REVIEW
The directors are satisfied with the financial performance of the group for the year.

Turnover amounted to £20.3m for the year compared to £18.6m in 2024.

Operating profit before tax was £2.57m compared to £1.79m in 2024.

The consolidated accounts for the year to September 2025 include a depreciation write off of £71k in respect of discontinued activities in MFC International Limited.

The group invested £456k in fixed assets during the year indicating the directors' and shareholders' continued commitment to the business.

The working capital position of the group improved to £13.1m at the year end.

Shareholders' funds increased to £18.5m at the year end.

PRINCIPAL RISKS & UNCERTAINTIES
We see ourselves as global operators and throughout our group of companies, we will follow that philosophy. We have carried out the necessary work to ensure that all our products are certified to the new European Regulations, and, where applicable US and other regional standards, that are vital to any business operating in the PPE and emergency services market. We also continue to broaden our customer base worldwide, working with specialist distributors. We are spending increasing amounts on our marketing budget in order to reach a broader audience for our products.

Our main risks revolve around the political and economic uncertainties that continue to prevail in the United Kingdom and beyond. These uncertainties carry all the obvious concerns around currency and ever increasing world tensions, in addition to higher energy costs rising labour cost and supply chain issues.

The group has invested considerable money in new products which will be launched later in 2026. The group will continue to invest in new and innovative products together with the introduction of more efficient manufacturing methods

These new products will take us into new territory and gives us the opportunity to take advantage of the opportunities we have identified. Our investment in new equipment will give us the ability to meet the increase in demand that we feel will flow from the world economy getting back to some normality. However, the business area in which the group operates is in great demand.


Respirex International Limited (Registered number: 00592506)

Group Strategic Report
for the Year Ended 30 September 2025

FUTURE PLANS
Respirex will continue to invest in the development of new products and grow its distributor network worldwide in order to expand market share and profitability. With growing sales and a respected global brand plus our reputation for technical expertise and quality, we are in a strong position to take advantage of all opportunities that present themselves.

ON BEHALF OF THE BOARD:





M B Simpson - Director


18 June 2026

Respirex International Limited (Registered number: 00592506)

Report of the Directors
for the Year Ended 30 September 2025

The directors present their report with the financial statements of the company and the group for the year ended 30 September 2025.

PRINCIPAL ACTIVITY
The principal activity of the group in the year under review was that of manufacture and supply of industrial and safety equipment.

DIVIDENDS
The directors do not recommend the payment of a dividend.

DIRECTORS
The directors shown below have held office during the whole of the period from 1 October 2024 to the date of this report.

M B Simpson
G Walker
A Burt

STATEMENT OF DIRECTORS' RESPONSIBILITIES
The directors are responsible for preparing the Group Strategic Report, the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law), including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the group and of the profit or loss of the group for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's and the group's transactions and disclose with reasonable accuracy at any time the financial position of the company and the group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS
So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the group's auditors are unaware, and each director has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the group's auditors are aware of that information.

ON BEHALF OF THE BOARD:





M B Simpson - Director


18 June 2026

Report of the Independent Auditors to the Members of
Respirex International Limited

Opinion
We have audited the financial statements of Respirex International Limited (the 'parent company') and its subsidiaries (the 'group') for the year ended 30 September 2025 which comprise the Consolidated Income Statement, Consolidated Other Comprehensive Income, Consolidated Statement of Financial Position, Company Statement of Financial Position, Consolidated Statement of Changes in Equity, Company Statement of Changes in Equity, Consolidated Statement of Cash Flows and Notes to the Consolidated Statement of Cash Flows, Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:
-give a true and fair view of the state of the group's and of the parent company affairs as at 30 September 2025 and of the group's profit for the year then ended;
-have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
-have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and the parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information
The directors are responsible for the other information. The other information comprises the information in the Group Strategic Report and the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Group Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Group Strategic Report and the Report of the Directors have been prepared in accordance with applicable legal requirements.

Report of the Independent Auditors to the Members of
Respirex International Limited


Matters on which we are required to report by exception
In the light of the knowledge and understanding of the group and the parent company and its environment obtained in the course of the audit, we have not identified material misstatements in the Group Strategic Report or the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:
- adequate accounting records have not been kept by the parent company, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of directors
As explained more fully in the Statement of Directors' Responsibilities set out on page four, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the group's and the parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the group or the parent company or to cease operations, or have no realistic alternative but to do so.

Report of the Independent Auditors to the Members of
Respirex International Limited


Auditors' responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

The objectives of our audit in respect of fraud are to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses to those assessed risks and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the company.

Our approach was as follows:
- we obtained an understanding of the legal and regulatory requirements applicable to the group.
- we obtained an understanding of how the group complies with these requirements through discussion with management and those charged with governance.
- we assessed the risk of material misstatement in the financial statements through discussions with management and those charged with governance.
- we enquired of management and those charged with governance of any known instances of non compliance with legal and regulatory requirements.
- based on this understanding, we designed specific and appropriate audit procedures to identify instances of non compliance to include discussions and obtaining additional corroborative evidence.

As part of the audit in accordance with ISAs (UK) we exercised professional judgement and scepticism throughout the audit. In addition, we also:

- identified and assessed the risks of material misstatement of the financial statements, whether due to fraud or error, designed and performed audit procedures consistent with those risks and obtained sufficient and relevant audit evidence to support and provide a basis for our opinion. The risk of misstatement from fraud is invariably higher than one resulting from error as fraud may involve collusion or intentional omissions and misrepresentations to override the systems of internal control.
- obtained an understanding of the internal controls relevant to the audit and designed
audit procedures and tests that were appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the company's internal controls.
- evaluated the appropriateness of the accounting policies used and the reasonableness of any accounting estimates and disclosures used and made by the directors.
- assessed the appropriateness of the directors' use of the going concern basis of accounting and based on the audit evidence obtained, whether any material uncertainty existed that may have cast doubt on the group's ability to continue as a going concern.
- evaluated the overall presentation, structure and content of the financial statements including disclosures and whether the financial statements represent the underlying transactions and events in a manner that achieved a fair presentation of the results for the period and the financial standing of the group at the period end.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

Report of the Independent Auditors to the Members of
Respirex International Limited


Use of our report
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.




Aidan Smyth (Senior Statutory Auditor)
for and on behalf of Peter Hodgson & Co. Ltd. (Statutory Auditor)
Chartered Accountants
Shadwell House
65 Lower Green Road
Tunbridge Wells
Kent
TN4 8TW

18 June 2026

Respirex International Limited (Registered number: 00592506)

Consolidated
Income Statement
for the Year Ended 30 September 2025

2025 2024
Notes £    £    £    £   

REVENUE 3 20,345,031 18,550,381

Cost of sales 12,949,489 12,300,018
GROSS PROFIT 7,395,542 6,250,363

Administrative expenses 4,879,676 4,701,428
2,515,866 1,548,935

Other operating income 8,650 8,851
OPERATING PROFIT 6 2,524,516 1,557,786

Income from fixed asset investments 22,082 10,291
Interest receivable and similar income 36 20
22,118 10,311
2,546,634 1,568,097
Market value adjustments 7 (161,958 ) (399,356 )
2,708,592 1,967,453

Interest payable and similar expenses 8 144,654 168,848
PROFIT BEFORE TAXATION 2,563,938 1,798,605

Tax on profit 9 451,261 172,988
PROFIT FOR THE FINANCIAL YEAR 2,112,677 1,625,617
Profit attributable to:
Owners of the parent 2,112,677 1,625,617

Respirex International Limited (Registered number: 00592506)

Consolidated
Other Comprehensive Income
for the Year Ended 30 September 2025

2025 2024
Notes £    £   

PROFIT FOR THE YEAR 2,112,677 1,625,617


OTHER COMPREHENSIVE INCOME - -
TOTAL COMPREHENSIVE INCOME
FOR THE YEAR

2,112,677

1,625,617

Total comprehensive income attributable to:
Owners of the parent 2,112,677 1,625,617

Respirex International Limited (Registered number: 00592506)

Consolidated Statement of Financial Position
30 September 2025

2025 2024
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 11 403,001 378,522
Property, plant and equipment 12 6,471,479 6,717,842
Investments 13
Interest in associate 49,646 49,646
6,924,126 7,146,010

CURRENT ASSETS
Inventories 14 7,622,564 7,448,433
Debtors 15 5,007,248 4,263,299
Investments 16 3,793,230 3,609,190
Cash at bank 2,529,545 1,001,458
18,952,587 16,322,380
CREDITORS
Amounts falling due within one year 17 5,815,265 5,134,454
NET CURRENT ASSETS 13,137,322 11,187,926
TOTAL ASSETS LESS CURRENT
LIABILITIES

20,061,448

18,333,936

CREDITORS
Amounts falling due after more than one
year

18

(1,012,633

)

(1,394,204

)

PROVISIONS FOR LIABILITIES 22 (512,101 ) (515,695 )
NET ASSETS 18,536,714 16,424,037

CAPITAL AND RESERVES
Called up share capital 23 948 948
Capital redemption reserve 24 52 52
Other reserves 24 1,191 1,191
Retained earnings 24 18,534,523 16,421,846
SHAREHOLDERS' FUNDS 18,536,714 16,424,037

The financial statements were approved by the Board of Directors and authorised for issue on 18 June 2026 and were signed on its behalf by:





M B Simpson - Director


Respirex International Limited (Registered number: 00592506)

Company Statement of Financial Position
30 September 2025

2025 2024
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 11 400,824 376,072
Property, plant and equipment 12 5,117,833 5,226,287
Investments 13 517,566 517,566
6,036,223 6,119,925

CURRENT ASSETS
Inventories 14 6,279,632 5,999,108
Debtors 15 11,144,295 10,341,885
Investments 16 3,793,230 3,609,190
Cash at bank 2,225,125 805,525
23,442,282 20,755,708
CREDITORS
Amounts falling due within one year 17 5,479,731 4,771,589
NET CURRENT ASSETS 17,962,551 15,984,119
TOTAL ASSETS LESS CURRENT
LIABILITIES

23,998,774

22,104,044

CREDITORS
Amounts falling due after more than one
year

18

(1,012,633

)

(1,385,152

)

PROVISIONS FOR LIABILITIES 22 (466,374 ) (443,729 )
NET ASSETS 22,519,767 20,275,163

CAPITAL AND RESERVES
Called up share capital 23 948 948
Capital redemption reserve 24 52 52
Other reserves 24 1,191 1,191
Retained earnings 24 22,517,576 20,272,972
SHAREHOLDERS' FUNDS 22,519,767 20,275,163

Company's profit for the financial year 2,244,604 2,102,771

The financial statements were approved by the Board of Directors and authorised for issue on 18 June 2026 and were signed on its behalf by:





M B Simpson - Director


Respirex International Limited (Registered number: 00592506)

Consolidated Statement of Changes in Equity
for the Year Ended 30 September 2025

Called up Capital
share Retained redemption Other Total
capital earnings reserve reserves equity
£    £    £    £    £   
Balance at 1 October 2023 948 14,796,229 52 1,191 14,798,420

Changes in equity
Total comprehensive income - 1,625,617 - - 1,625,617
Balance at 30 September 2024 948 16,421,846 52 1,191 16,424,037

Changes in equity
Total comprehensive income - 2,112,677 - - 2,112,677
Balance at 30 September 2025 948 18,534,523 52 1,191 18,536,714

Respirex International Limited (Registered number: 00592506)

Company Statement of Changes in Equity
for the Year Ended 30 September 2025

Called up Capital
share Retained redemption Other Total
capital earnings reserve reserves equity
£    £    £    £    £   
Balance at 1 October 2023 948 18,170,201 52 1,191 18,172,392

Changes in equity
Total comprehensive income - 2,102,771 - - 2,102,771
Balance at 30 September 2024 948 20,272,972 52 1,191 20,275,163

Changes in equity
Total comprehensive income - 2,244,604 - - 2,244,604
Balance at 30 September 2025 948 22,517,576 52 1,191 22,519,767

Respirex International Limited (Registered number: 00592506)

Consolidated Statement of Cash Flows
for the Year Ended 30 September 2025

2025 2024
Notes £    £   
Cash flows from operating activities
Cash generated from operations 1 2,741,580 1,144,548
Interest paid (144,654 ) (105,256 )
Foreign exchange (losses) / gains - (63,592 )
Tax paid (125,400 ) (108,179 )
Net cash from operating activities 2,471,526 867,521

Cash flows from investing activities
Purchase of intangible fixed assets (25,368 ) (10,924 )
Purchase of tangible fixed assets (455,525 ) (709,012 )
Sale of tangible fixed assets 41,000 148,861
Interest received 36 20
Dividends received 22,082 10,291
Net cash from investing activities (417,775 ) (560,764 )

Cash flows from financing activities
New loans in year 39,559 258,609
Capital repayments in year (565,351 ) (600,671 )
Amount introduced by directors 128 66,952
Net cash from financing activities (525,664 ) (275,110 )

Increase in cash and cash equivalents 1,528,087 31,647
Cash and cash equivalents at beginning of
year

2

1,001,458

969,811

Cash and cash equivalents at end of year 2 2,529,545 1,001,458

Respirex International Limited (Registered number: 00592506)

Notes to the Consolidated Statement of Cash Flows
for the Year Ended 30 September 2025

1. RECONCILIATION OF PROFIT BEFORE TAXATION TO CASH GENERATED FROM
OPERATIONS

2025 2024
£    £   
Profit before taxation 2,563,938 1,798,605
Depreciation charges 672,808 631,203
Profit on disposal of fixed assets (5,329 ) (12,977 )
Finance costs 144,654 168,848
Finance income (22,118 ) (10,311 )
3,353,953 2,575,368
Increase in inventories (174,131 ) (292,874 )
Increase in trade and other debtors (722,349 ) (222,167 )
Increase/(decrease) in trade and other creditors 284,107 (915,779 )
Cash generated from operations 2,741,580 1,144,548

2. CASH AND CASH EQUIVALENTS

The amounts disclosed on the Statement of Cash Flows in respect of cash and cash equivalents are in respect of these Statement of Financial Position amounts:

Year ended 30 September 2025
30.9.25 1.10.24
£    £   
Cash and cash equivalents 2,529,545 1,001,458
Year ended 30 September 2024
30.9.24 1.10.23
£    £   
Cash and cash equivalents 1,001,458 969,811


Respirex International Limited (Registered number: 00592506)

Notes to the Consolidated Statement of Cash Flows
for the Year Ended 30 September 2025

3. ANALYSIS OF CHANGES IN NET FUNDS

At 1.10.24 Cash flow At 30.9.25
£    £    £   
Net cash
Cash at bank 1,001,458 1,528,087 2,529,545
1,001,458 1,528,087 2,529,545

Liquid resources
Current asset investments 3,609,190 184,040 3,793,230
3,609,190 184,040 3,793,230
Debt
Finance leases (563,571 ) 246,816 (316,755 )
Debts falling due within 1 year (267,474 ) 50,885 (216,589 )
Debts falling due after 1 year (995,887 ) 228,091 (767,796 )
(1,826,932 ) 525,792 (1,301,140 )
Total 2,783,716 2,237,919 5,021,635

Respirex International Limited (Registered number: 00592506)

Notes to the Consolidated Financial Statements
for the Year Ended 30 September 2025

1. STATUTORY INFORMATION

Respirex International Limited is a private company, limited by shares and incorporated in England and Wales.

The company's registered office and registered number can be found on the General Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Basis of consolidation
The accounts consolidate the trading results of Respirex International Limited for the year ended 30 September 2025 with the trading results of the following wholly owned subsidiaries:

MFC International Limited
KTC Fire Limited (dormant)
Respirex GMBH

The accounts for each subsidiary company are drawn up to 30th September 2025.

All inter-group transactions are eliminated on consolidation.

Significant judgements and estimates
Other than depreciation, there are no significant judgements or estimates pertaining to these accounts.

Turnover
Revenue is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Patents, licenses and trademarks are being amortised evenly over their estimated useful life of nil years.

Patents, licenses and trademarks
The costs of patents, licenses and trademarks are capitalised and are not depreciated.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Freehold property - 2% on cost (buildings only)
Plant and machinery - 15% on reducing balance
Fixtures and fittings - 25% straight line and 15% on reducing balance
Motor vehicles - 25% on reducing balance and 25% straight line
Computer equipment - 25 - 33.3% on reducing balance

Investments in associates
Investments in associated undertakings are recognised at cost less provision for impairments.

Stocks
Inventories are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.


Respirex International Limited (Registered number: 00592506)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 30 September 2025

2. ACCOUNTING POLICIES - continued
Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Consolidated Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research and development
Expenditure on research and development is written off in the year in which it is incurred.


Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the statement of financial position date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Pension costs and other post-retirement benefits
The group operates a defined contribution pension scheme. Contributions payable to the group's pension scheme are charged to profit or loss in the period to which they relate.

Functional currency
The functional currencies used by the group are £ Stg, $USD and €.

The accounts are presented in £Stg.

Loose tools
The cost of loose tools such as dies, bits and cutting heads is charged to profit in the year in which it is incurred.

Financial instruments
Basic financial instruments comprising debtors, bank and cash balances are stated at fair value.

Listed investments are stated at fair market value at the period end. Changes to market value from the previous period end are recognised through the income statement.

Respirex International Limited (Registered number: 00592506)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 30 September 2025

3. REVENUE

The revenue and profit before taxation are attributable to the one principal activity of the group.

An analysis of revenue by geographical market is given below:

2025 2024
£    £   
United Kingdom 10,901,631 7,959,085
Europe 3,909,200 5,450,214
United States of America 2,870,055 3,774,219
Rest of world 2,664,145 1,366,863
20,345,031 18,550,381

4. EMPLOYEES AND DIRECTORS
2025 2024
£    £   
Wages and salaries 5,454,943 5,565,247
Social security costs 684,150 581,894
Other pension costs 90,697 111,231
6,229,790 6,258,372

The average number of employees during the year was as follows:
2025 2024

Production 102 104
Sales & administration 28 31
130 135

5. DIRECTORS' EMOLUMENTS
2025 2024
£    £   
Directors' remuneration 415,595 428,570

The number of directors to whom retirement benefits were accruing was as follows:

Money purchase schemes 5 5

Information regarding the highest paid director is as follows:
2025 2024
£    £   
Emoluments etc 137,766 93,781

Pension contributions paid on behalf of 5 directors amounted to £29,812.

Respirex International Limited (Registered number: 00592506)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 30 September 2025

6. OPERATING PROFIT

The operating profit is stated after charging/(crediting):

2025 2024
£    £   
Depreciation - owned assets 666,217 630,510
Profit on disposal of fixed assets (5,329 ) (12,977 )
Patents, licenses and trademarks amortisation 889 693
Auditors' remuneration 13,700 12,800

7. MARKET VALUE ADJUSTMENTS
2025 2024
£    £   
Decrease / (increase)
in market value (161,958 ) (399,356 )

8. INTEREST PAYABLE AND SIMILAR EXPENSES
2025 2024
£    £   
Bank interest and charges 63,171 79,037
Hire purchase interest 30,813 26,219
Foreign exchange differences 50,670 63,592
144,654 168,848

9. TAXATION

Analysis of the tax charge
The tax charge on the profit for the year was as follows:
2025 2024
£    £   
Current tax:
UK corporation tax 454,855 125,400

Deferred tax (3,594 ) 47,588
Tax on profit 451,261 172,988

Respirex International Limited (Registered number: 00592506)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 30 September 2025

9. TAXATION - continued

Reconciliation of total tax charge included in profit and loss
The tax assessed for the year is lower than the standard rate of corporation tax in the UK. The difference is explained below:

2025 2024
£    £   
Profit before tax 2,563,938 1,798,605
Profit multiplied by the standard rate of corporation tax in the UK of 25 %
(2024 - 25 %)

640,985

449,651

Effects of:
Expenses not deductible for tax purposes 22,012 1,600
Depreciation in excess of capital allowances 65,803 14,624
Research & development tax credit adjustments (214,874 ) (196,477 )
FRS102 funding adjustment 1,258 1,207
Change in market value of investments (40,489 ) (99,839 )
Dividend income not taxable (5,520 ) (2,572 )
Pension charges (15,000 ) 15,000
Foreign subsidiary not taxed in UK (2,914 ) (10,206 )
Total tax charge 451,261 172,988

10. INDIVIDUAL INCOME STATEMENT

As permitted by Section 408 of the Companies Act 2006, the Income Statement of the parent company is not presented as part of these financial statements.


11. INTANGIBLE FIXED ASSETS

Group
Patents,
licenses
and
trademarks
£   
COST
At 1 October 2024 385,816
Additions 25,368
At 30 September 2025 411,184
AMORTISATION
At 1 October 2024 7,294
Amortisation for year 889
At 30 September 2025 8,183
NET BOOK VALUE
At 30 September 2025 403,001
At 30 September 2024 378,522

Respirex International Limited (Registered number: 00592506)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 30 September 2025

11. INTANGIBLE FIXED ASSETS - continued

Company
Patents,
licenses
and
trademarks
£   
COST
At 1 October 2024 376,072
Additions 24,752
At 30 September 2025 400,824
NET BOOK VALUE
At 30 September 2025 400,824
At 30 September 2024 376,072

12. PROPERTY, PLANT AND EQUIPMENT

Group
Fixtures
Freehold Plant and and
property machinery fittings
£    £    £   
COST
At 1 October 2024 4,343,277 8,761,813 360,042
Additions 20,637 350,024 5,518
Disposals - (176,820 ) -
At 30 September 2025 4,363,914 8,935,017 365,560
DEPRECIATION
At 1 October 2024 389,764 6,404,398 319,254
Charge for year 65,142 479,496 9,212
Eliminated on disposal - (154,023 ) -
At 30 September 2025 454,906 6,729,871 328,466
NET BOOK VALUE
At 30 September 2025 3,909,008 2,205,146 37,094
At 30 September 2024 3,953,513 2,357,415 40,788

Respirex International Limited (Registered number: 00592506)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 30 September 2025

12. PROPERTY, PLANT AND EQUIPMENT - continued

Group

Motor Computer
vehicles equipment Totals
£    £    £   
COST
At 1 October 2024 569,361 407,203 14,441,696
Additions 64,444 14,902 455,525
Disposals (75,965 ) (100,000 ) (352,785 )
At 30 September 2025 557,840 322,105 14,544,436
DEPRECIATION
At 1 October 2024 252,959 357,479 7,723,854
Charge for year 92,253 20,114 666,217
Eliminated on disposal (63,091 ) (100,000 ) (317,114 )
At 30 September 2025 282,121 277,593 8,072,957
NET BOOK VALUE
At 30 September 2025 275,719 44,512 6,471,479
At 30 September 2024 316,402 49,724 6,717,842

Included in the group fixed assets are assets held under hire purchase contracts.

The net book value of these assets at the year end for the group amounted to £487,488 and the amount of hire purchase outstanding on these assets by the group was £316,755.

Company
Fixtures
Freehold Plant and and
property machinery fittings
£    £    £   
COST
At 1 October 2024 3,036,305 7,678,594 197,257
Additions 20,637 350,024 5,518
Disposals - (176,820 ) -
At 30 September 2025 3,056,942 7,851,798 202,775
DEPRECIATION
At 1 October 2024 220,399 5,665,751 163,831
Charge for year 43,003 354,980 7,475
Eliminated on disposal - (154,023 ) -
At 30 September 2025 263,402 5,866,708 171,306
NET BOOK VALUE
At 30 September 2025 2,793,540 1,985,090 31,469
At 30 September 2024 2,815,906 2,012,843 33,426

Respirex International Limited (Registered number: 00592506)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 30 September 2025

12. PROPERTY, PLANT AND EQUIPMENT - continued

Company

Motor Computer
vehicles equipment Totals
£    £    £   
COST
At 1 October 2024 544,084 407,203 11,863,443
Additions 49,449 14,902 440,530
Disposals (66,716 ) (100,000 ) (343,536 )
At 30 September 2025 526,817 322,105 11,960,437
DEPRECIATION
At 1 October 2024 229,696 357,479 6,637,156
Charge for year 87,741 20,114 513,313
Eliminated on disposal (53,842 ) (100,000 ) (307,865 )
At 30 September 2025 263,595 277,593 6,842,604
NET BOOK VALUE
At 30 September 2025 263,222 44,512 5,117,833
At 30 September 2024 314,388 49,724 5,226,287

Included in fixed assets are assets held under hire purchase contracts.

The net book value of these assets at the year end amounted to £487,488 and the amount of hire purchase outstanding on them was £316,755.

13. FIXED ASSET INVESTMENTS

Group
Interest
in
associate
£   
COST
At 1 October 2024
and 30 September 2025 49,646
NET BOOK VALUE
At 30 September 2025 49,646
At 30 September 2024 49,646

Respirex International Limited (Registered number: 00592506)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 30 September 2025

13. FIXED ASSET INVESTMENTS - continued

Company
Shares in Interest
group in
undertakings associate Totals
£    £    £   
COST
At 1 October 2024
and 30 September 2025 467,920 49,646 517,566
NET BOOK VALUE
At 30 September 2025 467,920 49,646 517,566
At 30 September 2024 467,920 49,646 517,566

The group or the company's investments at the Statement of Financial Position date in the share capital of companies include the following:

Subsidiaries

MFC International Limited
Registered office: Shadwell House, 65 Lower Green Road, Tunbridge Wells, Kent TN4 8TW
Nature of business: supplier of inflatable and survival equipment.
%
Class of shares: holding
Ordinary 100.00
2025 2024
£    £   
Aggregate capital and reserves (3,140,221 ) (2,996,637 )
Loss for the year (143,584 ) (517,978 )

KTC Fire Limited
Registered office: Shadwell House, 65 Lower Green Road, Tunbridge Wells, Kent TN4 8TW
Nature of business: not trading
%
Class of shares: holding
Ordinary 100.00
2025 2024
£    £   
Aggregate capital and reserves 100 100

Respirex GMBH
Registered office: Wilthener Strasse, 32-02625 Bautzen, Germany
Nature of business: supplier of industrial safety equipment
%
Class of shares: holding
Ordinary 100.00
2025 2024
£    £   
Aggregate capital and reserves (375,013 ) (386,669 )
Profit for the year 11,656 40,824

Respirex International Limited (Registered number: 00592506)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 30 September 2025

13. FIXED ASSET INVESTMENTS - continued

Associated company

Respirex France Limited
Registered office: 4B Chemin des Clos, 78830 Bonnelles, France
Nature of business: supplier of industrial safety equipment.
%
Class of shares: holding
Ordinary 40.00
31.12.24 31.12.23
£    £   
Aggregate capital and reserves 274,304 132,123
Profit for the year 141,815 84,010


14. STOCKS

Group Company
2025 2024 2025 2024
£    £    £    £   
Stock & work in progress 7,622,564 7,448,433 6,279,632 5,999,108

15. DEBTORS

Group Company
2025 2024 2025 2024
£    £    £    £   
Amounts falling due within one year:
Trade debtors 3,735,660 2,710,022 3,735,527 2,871,836
Due from related parties 160,333 238,211 155,649 238,211
VAT - 65,384 - 65,001
Prepayments & other debtors 1,111,255 1,249,682 943,432 1,004,236
5,007,248 4,263,299 4,834,608 4,179,284

Amounts falling due after more than one year:
Amounts owed by group undertakings - - 6,309,687 6,162,601

Aggregate amounts 5,007,248 4,263,299 11,144,295 10,341,885

Group loan balances due to Respirex International Limited at 30 September 2025 were as follows:

MFC International Limited - £6,279,257.
Respirex GMBH - £30,430.

Both loans are on an interest free basis and are due after more than one year with no formal repayment terms.

Respirex International Limited (Registered number: 00592506)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 30 September 2025

16. CURRENT ASSET INVESTMENTS

There were no realised gains on the investment portfolio in either the current or previous years.

An unrealised gain of £161,958 was recognised for the year (2024 : unrealised gain of £399,356).

Dividend income earned in the year amounted to £22,082 ( 2024 : £10,291).

17. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

Group Company
2025 2024 2025 2024
£    £    £    £   
Bank loans and overdrafts (see note 19) 216,589 267,474 207,826 257,474
Hire purchase contracts (see note 20) 197,681 285,987 197,681 285,987
Trade creditors 1,391,307 1,390,992 1,258,926 1,260,517
Corporation tax 454,855 125,400 506,471 125,400
VAT 300,930 - 306,618 -
Deferred revenue 2,304,820 2,421,938 2,304,820 2,421,938
PAYE & social security 318,152 135,225 301,722 112,000
Directors' current accounts 2,988 2,860 2,988 2,860
Accruals & others 587,370 486,047 352,106 286,882
Due to related parties 40,573 18,531 40,573 18,531
5,815,265 5,134,454 5,479,731 4,771,589

Bank borrowings are secured by a debenture over all current and future assets of the group.

18. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR

Group Company
2025 2024 2025 2024
£    £    £    £   
Bank loans (see note 19) 767,796 995,887 767,796 986,835
Hire purchase contracts (see note 20) 119,074 277,584 119,074 277,584
Loan from former shareholder 125,763 120,733 125,763 120,733
1,012,633 1,394,204 1,012,633 1,385,152

Bank borrowings are secured by a debenture over all current and future assets of the group.

Respirex International Limited (Registered number: 00592506)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 30 September 2025

19. LOANS

An analysis of the maturity of loans is given below:

Group Company
2025 2024 2025 2024
£    £    £    £   
Amounts falling due within one year or on demand:
Bank loan repayment 216,589 267,474 207,826 257,474
Amounts falling due between one and two years:
Bank loans - 1-2 years 209,826 210,000 209,826 210,000
Amounts falling due between two and five years:
Bank loans - 2-5 years 557,970 659,052 557,970 650,000
Amounts falling due in more than five years:
Repayable by instalments
Bank loans > 5 years - 126,835 - 126,835

20. LEASING AGREEMENTS

Minimum lease payments fall due as follows:

Group
Hire purchase
contracts
2025 2024
£    £   
Net obligations repayable:
Within one year 197,681 285,987
Between one and five years 119,074 277,584
316,755 563,571

Company
Hire purchase
contracts
2025 2024
£    £   
Net obligations repayable:
Within one year 197,681 285,987
Between one and five years 119,074 277,584
316,755 563,571

Respirex International Limited (Registered number: 00592506)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 30 September 2025

20. LEASING AGREEMENTS - continued

Company
Non-cancellable
operating leases
2025 2024
£    £   
Within one year 65,500 65,500
Between one and five years 327,500 327,500
In more than five years 65,500 131,000
458,500 524,000

The operating lease commitments relates to a lease on Unit D Kingsfield Business Centre, Redhill which is rented under a 10 year lease dated 29 September 2022 at an annual rental of £65,500.

The lease expires on 29 September 2032 with a break clause after 5 years.

21. LOAN FROM FORMER SHAREHOLDER

The long term loan from a former shareholder of £131,001 is for a term of 10 years ending 30th September 2026 and is discounted at an assumed interest rate of 4%.

The net present value of the loan at 30 September 2025 was £125,763.

22. PROVISIONS FOR LIABILITIES

Group Company
2025 2024 2025 2024
£    £    £    £   
Deferred tax 512,101 515,695 466,374 443,729

Group
Deferred
tax
£   
Balance at 1 October 2024 515,695
Provided during year (3,594 )
Balance at 30 September 2025 512,101

Company
Deferred
tax
£   
Balance at 1 October 2024 443,729
Provided during year 22,645
Balance at 30 September 2025 466,374

Respirex International Limited (Registered number: 00592506)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 30 September 2025

23. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2025 2024
value: £    £   
948 Ordinary £1 948 948

24. RESERVES

Group
Capital
Retained redemption Other
earnings reserve reserves Totals
£    £    £    £   

At 1 October 2024 16,421,846 52 1,191 16,423,089
Profit for the year 2,112,677 2,112,677
At 30 September 2025 18,534,523 52 1,191 18,535,766

Company
Capital
Retained redemption Other
earnings reserve reserves Totals
£    £    £    £   

At 1 October 2024 20,272,972 52 1,191 20,274,215
Profit for the year 2,244,604 2,244,604
At 30 September 2025 22,517,576 52 1,191 22,518,819


25. RELATED PARTY DISCLOSURES

At the year end, the group was owed £160,333 by related parties.

At the year date, the group owed £40,573 to related parties.

Sales and services supplied to related parties amounted to £767,708 and bought in goods and services from related parties amounted to £806,685 during the year.

Services purchased from related parties include £679,685 management fees billed by Mamoda LLP. The directors; M B Simpson and D G Mackie were both employed by Mamoda LLP and their salaries are recharged at cost to the group.

26. ULTIMATE CONTROLLING PARTY

The controlling party is M B Simpson.

The group was under the control of M B Simpson in the current and previous financial years.

Respirex International Limited (Registered number: 00592506)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 30 September 2025

27. CONSOLIDATED ACCOUNTS & GROUP BALANCES

The accounts consolidate the trading results of Respirex International Limited for the year ended 30 September 2025 with the trading results of the following wholly owned subsidiaries:

MFC International Limited (audited)
KTC Fire Limited (dormant)
Respirex GMBH (not audited)

The accounts for each subsidiary company are drawn up to 30th September 2025.

All transactions between group members are eliminated from the group accounts and all result from trading activities between the group members.

Group loan balances due to Respirex International Limited at 30 September 2025 were as follows:

MFC International Limited - £6,279,257.
Respirex GMBH - £30,430.

Both loans are on an interest free basis and are due after more than one year with no formal repayment terms.

28. DIRECTOR'S LOAN

At the balance sheet date, A Burt was owed £2,988 by the group.

The loan is non interest bearing and there are no formal repayment terms attaching to it.